A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

March 26, 2014

Primary Completion Date

June 20, 2017

Study Completion Date

June 20, 2017

Conditions
Schizophrenia
Interventions
DRUG

Valacyclovir HCI 500 mg tablets

Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks

DRUG

placebo

placebo capsules 6/day oral for 16 weeks

Trial Locations (13)

20850

Centers for Behavioral Health, LLC, Rockville

21204

Sheppard Pratt Health System, Towson

21228

Maryland Psychiatric Research Center, Baltimore

33319

Innovative Clinical Research, Inc., Lauderhill

46202

Prevention and Recovery Center for Early Psychosis, Indianapolis

46222

Indiana University Psychotic Disorders Clinic, Indianapolis

67214

University of Kansas Medical Center-Witchita, Wichita

74136

Laureate Institute for Brain Research, Tulsa

90095

University of California, Los Angeles, Los Angeles

90706

C.I. Trials, Inc.-Los Angeles County, Bellflower

92506

University of California, Riverside at C.I. Trials, Inc.-Inland Empire, Riverside

92705

C.I. Trials, Inc.-Orange County, Santa Ana

06519

Yale University, New Haven

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

collaborator

Sheppard Pratt Health System

OTHER

collaborator

University of Maryland

OTHER

collaborator

Centers for Behavioral Health, LLC

UNKNOWN

collaborator

Laureate Institute for Brain Research, Inc.

OTHER

collaborator

University of Kansas Medical Center

OTHER

collaborator

University of California, Los Angeles

OTHER

collaborator

Yale University

OTHER

collaborator

Innovative Clinical Research, Inc.

INDUSTRY

collaborator

University of California Riverside at C.I. Trials, Inc.-Inland Empire

UNKNOWN

collaborator

Clinical Innovations

INDUSTRY

lead

Indiana University

OTHER